...
【24h】

Persistent disease in patients with papillary thyroid carcinoma and lymph node metastases after surgery and iodine-131 ablation.

机译:甲状腺乳头状癌患者的持续性疾病以及手术和碘131消融后的淋巴结转移。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

AIM: The aim of this study was to assess the efficacy of treatment of patients with papillary thyroid carcinoma (PTC) and lymph node metastases at the time of diagnosis and its influence on the course of the disease. METHODS: It is a retrospective review of all 51 patients with PTC and histologically proven lymph node metastases treated with I-131 ablation in our center between January 1990 and January 2003. Patients were considered disease-free if during follow-up thyroglobulin levels were undetectable and scintigraphy with 370 MBq (131)I was negative during thyroid-stimulating hormone stimulation. Staging of patients was in accordance with the 5th edition of the TNM system. RESULTS: After a median follow-up of 84 months, 33 (65%) patients were never free of detectable disease; and 3 of these patients had died of the PTC. In total, 22 patients still showed persistent activity in the neck outside the thyroid bed, which was suspect to be cervical lymph node metastasis on postablation scintigraphy; it was not related to the initial clinical presentation (lymph node metastasis or a thyroid nodule without suspicion of metastatic disease) or to the extent of surgery. Altogether, 34 patients required additional treatment. Patients presenting with clinically overt lymph node metastasis showed a significantly (p = 0.022) lower rate of becoming disease-free than those in whom microscopic lymph node involvement was unexpectedly found upon pathologic examination. There was no significant association of the eventual outcome with the extent of surgical treatment, TNM staging, or age. CONCLUSIONS: Patients with lymph node metastasis are considerably less likely to become disease-free. If the initial treatment does not result in a disease-free status, chances are low that additional treatment will succeed in achieving it.
机译:目的:本研究的目的是评估诊断时乳头状甲状腺癌(PTC)和淋巴结转移的患者的治疗效果及其对疾病进程的影响。方法:这是一项回顾性研究,回顾性分析了1990年1月至2003年1月在我中心接受I-131消融治疗的所有51例PTC并经组织学证实的淋巴结转移的患者。如果在随访期间未检测到甲状腺球蛋白水平,则认为患者无病370 MBq(131)I闪烁显像在甲状腺刺激激素刺激过程中呈阴性。患者分期符合TNM系统第5版。结果:在中位随访84个月后,有33名患者(65%)从来没有发现可检测的疾病。其中3名患者死于PTC。总共有22例患者仍显示甲状腺床外颈部持续活动,在消融后闪烁显像术中怀疑是颈部淋巴结转移。它与最初的临床表现(淋巴结转移或无怀疑转移性疾病的甲状腺结节)或手术范围无关。共有34例患者需要进一步治疗。与在病理检查中意外发现有微小淋巴结受累的患者相比,临床上明显存在淋巴结转移的患者无病发生率显着降低(p = 0.022)。最终结果与手术治疗程度,TNM分期或年龄没有显着相关性。结论:淋巴结转移患者无病的可能性大大降低。如果初始治疗未导致无病状态,则通过其他治疗成功实现这一目标的机会很小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号